CSIRO, the Commonwealth Scientific and Industrial Research Organisation news

CSIRO and ingredients manufacturer, Clover Corporation Limited, are developing the next generation of nutritional ingredients for infant formulas.

CSIRO and leading Australian ingredients manufacturer, Clover Corporation Limited, have agreed to work together on the development of the next generation of nutritional ingredients for infant formulas.

“While natural breast milk is the gold standard, when infant formulas are needed to supplement or repla

Dr Deborah Middleton from CSIRO’s Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the vaccine at the Australian Veterinary Association conference in Adelaide today.

“Our trials so far have shown that the vaccine prevents the infection of horses with Hendra virus,” Dr Middleton said.

Stopping the disease in horses could also help protect people from the disease.

“A horse vaccine is crucial to b

Alzheimer’s disease is one of the fastest growing diseases in Australia and the most common form of dementia.  The number of people with dementia is expected to rise from 300,000 to 1.13 million by 2050.

Alzheimer’s disease is associated with the development of a toxic protein in the brain known as amyloid beta. The amyloid beta protein rapidly self-assembles in the brain and builds up to form plaques which are a hallmark of the disease.

It is thought that the

RAFT technology has transformed polymer research and development and has already enabled the development of a number of new materials featuring much improved performance and functionality.

Now CSIRO and DuPont have accelerated their technology transfer and licensing program for RAFT with companies able to access the technology in three ways:

• The RAFT Label License for early stage research and development enables partners to purchase RAFT agents from chemical supply hous

Being conducted in collaboration with the Centre for Food and Genomic Medicine (CFGM) in Perth, WA, the three-year, $1.5 million project will enable researchers and breeders to accelerate lupin crop improvements such as drought tolerance, disease resistance and optimal flowering time.

The research team will build upon established resources and employ powerful next-generation sequencing technologies and innovative bioinformatics techniques in their efforts to sequence the genome.

The cluster will conduct the START (Stroke, imaging, pRevention and Treatment) cohort study of stroke which is designed to integrate imaging and biomarker analysis to identify patients at risk of stroke.

Those strategies will then be used to develop preventative measures for those patients.

The START Cohort will collect and analyse information derived from brain imaging and blood samples taken from 200 Australian stroke victims with the aim of discovering and validating new di

"Nutritional genomics is an emerging area of science that is making a significant difference in our approach to enhancing health outcomes by improving our understanding of how to prevent harmful genetic changes that cause developmental defects and degenerative diseases," says Professor Michael Fenech from CSIRO Food and Nutritional Sciences.

"In recent years, this research is probably best recognised for identifying how folate assists in reducing neural tube defects during pregnancy."

The CSIRO Preventative Health Flagship is calling for volunteers to try out a pilot ‘online social network’ in which they get access to free diet and health information, recipes and chat sessions.

CSIRO is asking participants to sign up for 12 weeks, starting in early August.

CSIRO ICT research scientist Dr Shlomo Berkovsky said the trial aims to understand how online tools, such as discussion groups and chat sessions, can play a role in providing social support to

The International Conference on Alzheimer"s disease in Hawaii heard that scientists from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) have identified advances in imaging and blood screening that will contribute to the earlier detection of Alzheimer’s.

About 250,000 Australians currently have Alzheimer’s disease, but numbers are anticipated to rise to 1.3 million in the next 40 years if there were not significant breakthroughs in preventio

Reversible Addition-Fragmentation chain Transfer (or RAFT) technology is an elegant and powerful polymerisation process that has given rise to a new branch of polymer chemistry.

RAFT enables the development of very complex molecules that can be used for a wide range of products. The technology is already generating major improvements in the areas of coatings and paints, electroactive materials, fuel additives, biomaterials, polymer synthesis, personal care, drug delivery agents and ca